DreamCIS, Inc.

A223250

KR7223250002

Healthcare Facilities & Services

End-of-day quote Korea S.E. Other stock markets 03:30:00 14/05/2024 am IST			5-day change	1st Jan Change
4,250 ^KRW	+0.71%		+10.39%	+30.57%

22/02	Curi Bio, Genetox and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay	CI
2023	T&R Biofab Co., Ltd. announced that it has received KRW 1.999996 billion in funding from Korea Investment Partners Co. Ltd., DreamCIS, Inc.	CI

DreamCIS, Inc. announced that it has received KRW 2.9999925 billion in funding

March 28, 2022

On March 28, 2022, DreamCIS, Inc. closed the transaction.

Latest news about DreamCIS, Inc.

Curi Bio, Genetox and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay	23/02	CI
T&R Biofab Co., Ltd. announced that it has received KRW 1.999996 billion in funding from Korea Investment Partners Co. Ltd., DreamCIS, Inc.	22/12	CI
T&R Biofab Co., Ltd. announced that it expects to receive KRW 1.999996 billion in funding from Korea Investment Partners Co. Ltd., DreamCIS, Inc.	14/12	CI
DreamCIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	22/23/22	CI
DreamCIS, Inc. announced that it has received KRW 2.9999925 billion in funding	28/22/28	CI
DreamCIS, Inc. announced that it expects to receive KRW 2.9999925 billion in funding	17/22/17	CI
DreamCIS, Inc. has completed an IPO in the amount of KRW 20.186311 billion.	21/20/21	CI
DreamCIS, Inc. has filed an IPO.	27/19/27	CI
Hangzhou Tigermed Consulting Co., Ltd. completed the acquisition of 98.14% stake in DreamCIS, Inc. from Leenos Corp. and Won-Young Choi.	22/15/22	CI
Hangzhou Tigermed Consulting Co., Ltd. signed letter of intent to acquire 70% stake in DreamCIS, Inc. from Leenos Corp. for KRW 27 billion.	08/15/08	CI
Leenos Corp. completed the acquisition of 70% stake in DreamCIS Inc. from Choi Won-Jung.	26/14/26	CI
Leenos Corp. signed an external valuation contract to acquire 70% stake in DreamCIS Inc. from Choi Won-Jung for KRW 13.1 billion.	17/14/17	CI

DreamCIS Inc is a Korea-based company principally engaged in the business of contract clinical trial. The Company mainly provides services include regulatory post-marketing surveillance (rPMS), clinical trial, non-interventional study (NIS) and others. The Company provides its services within domestic market and to overseas markets.

Sector

Healthcare Facilities & Services

Calendar

09/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
DREAMCIS, INC.	+30.57%	74.46M
SONIC HEALTHCARE LIMITED	-15.96%	8.57B
RADNET, INC.	+67.50%	4.3B
DR. LAL PATHLABS LIMITED	-4.03%	2.46B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-42.54%	2.31B
NEOGENOMICS, INC.	-6.49%	1.93B
FLEURY S.A.	-20.45%	1.53B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-41.24%	1.2B
METROPOLIS HEALTHCARE LIMITED	+10.26%	1.14B
VIJAYA DIAGNOSTIC CENTRE LIMITED	+18.74%	986M

Medical & Diagnostic Laboratories

DreamCIS, Inc.

Equities

A223250

KR7223250002

Healthcare Facilities & Services

DreamCIS, Inc. announced that it has received KRW 2.9999925 billion in funding

Latest news about DreamCIS, Inc.

Chart DreamCIS, Inc.

Company Profile

Income Statement Evolution

Sector Medical & Diagnostic Laboratories